In the BioHarmony Drug Report Database

"Preview" Icon

Macimorelin

Macrilen, Macimorelin Aeterna Zentaris (macimorelin) is a small molecule pharmaceutical. Macimorelin was first approved as Macrilen on 2017-12-20. It has been approved in Europe to treat endocrine diagnostic techniques. The pharmaceutical is active against growth hormone secretagogue receptor type 1. Macrilen’s patent is valid until 2027-10-12 (FDA).

 

Trade Name

 

Macimorelin Aeterna Zentaris
 

Common Name

 

macimorelin
 

ChEMBL ID

 

CHEMBL278623
 

Indication

 

endocrine diagnostic techniques
 

Drug Class

 

Prehormones or hormone-release stimulating peptides: growth hormone-release stimulating peptides

Image (chem structure or protein)

Macimorelin structure rendering